This is a routine Form 3 filing with no actionable trading signal. Monitor future Form 4 filings for any insider transactions that may indicate conviction or changes in outlook.
Price Chart
Executive Summary
John Michael Maraganore filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing his holdings in Hemab Therapeutics Holdings, Inc. (COAG). This is a routine filing required upon becoming an insider and contains no material financial information or trading activity.
Key Facts
- John Michael Maraganore filed Form 3 on April 30, 2026, disclosing beneficial ownership of Hemab Therapeutics Holdings, Inc. (COAG).
- Holdings include 17,974 shares of common stock (indirect), Series B and Series C Preferred Stock convertible into common stock, and warrants to purchase common stock at exercise prices of $2.16, $7.07, and $6.00 per share.
- The filing is a standard initial ownership report required under Section 16(a) of the Exchange Act, with no trading activity or material corporate event.
Financial Impact
No financial impact — filing is a routine insider ownership disclosure with no transaction or material change.
Risk Factors
- No material risks identified from this filing alone.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-198220 |
| Document: 0001193125-26-198220-index-headers.html | 0001193125-26-198220 |
| Document: 0001193125-26-198220-index.html | 0001193125-26-198220 |
| Document: 0001193125-26-198220.txt | 0001193125-26-198220 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $49.87 $44.50 | ▼ −10.77% | ▼ −9.71% | $30.36 (−39.12%) |
Jun 17, 2026 15w ago | Insider Buy | $29.24 $44.53 | ▲ +52.29% | ▲ +51.76% | $30.36 (+3.83%) |
May 21, 2026 19w ago | Press Release | $26.30 $31.83 | ▲ +21.03% | ▲ +20.69% | $30.36 (+15.44%) |
May 4, 2026 21w ago | 8-K | $25.00 $27.47 | ▲ +9.88% | ▲ +4.93% | $30.36 (+21.44%) |
Apr 30, 2026 22w ago | Press Release | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access